This week, not a surprise for leronlimab, I would
Post# of 154888
(Total Views: 519)
Posted On: 11/22/2019 8:18:44 PM
This week, not a surprise for leronlimab, I would be surprised if we see either of these in other hiv drugs
From the p2 mono paper
1)
At the two-year time point, seven of the 10 (70%) study participants had viral loads of less than 1 copy/mL using single-copy HIV RNA assay (bioMONTR lab), while the other three had values of 4, 10, and 19 copies/mL.
2)
Overall, PRO 140 was well tolerated with no related SAEs or discontinuation due to AEs observed in these studies. Other potential benefits of PRO 140 monotherapy include reductions in ART non-adherence and toxicity, along with reduction in other complaints related to intolerance of combination ART regimens
From the p2 mono paper
1)
At the two-year time point, seven of the 10 (70%) study participants had viral loads of less than 1 copy/mL using single-copy HIV RNA assay (bioMONTR lab), while the other three had values of 4, 10, and 19 copies/mL.
2)
Overall, PRO 140 was well tolerated with no related SAEs or discontinuation due to AEs observed in these studies. Other potential benefits of PRO 140 monotherapy include reductions in ART non-adherence and toxicity, along with reduction in other complaints related to intolerance of combination ART regimens
(2)
(0)